Elanco Animal Health Inc
NYSE:ELAN

  • LAST PRICE
    14.4300
  • TODAY'S CHANGE (%)
    0.1600 (1.1212%)
  • Bid / Lots
    14.4000/ 15
  • Ask / Lots
    14.7400/ 7
  • Open / Previous Close
    14.2500 / 14.2700
  • Day Range
    14.1600
    15.1200
  • 52 Week Range
    8.5200
    18.8000
  • Volume
    19,952,298

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

Charts

Price Comparison Graph. See accessible table below
Data delayed at least 15 minutes.

Pharmaceuticals - Generic & Specialty Industry Peers

CompanyMarket CapP/E Ratio (TTM)EPS Growth (5yr)
ELAN
Elanco Animal Health Inc
7.1B
-5.5x
---
PETQ
PetIQ Inc
656.3M
102.3x
---
PAHC
Phibro Animal Health Corp
679.2M
51.6x
-13.61%
SUPN
Supernus Pharmaceuticals Inc
1.5B
-94.1x
-59.02%
EGRX
Eagle Pharmaceuticals Inc
72.7M
6.1x
-4.75%
SGTI
Shengtai Pharmaceutical Inc
10.0
0.0x
---
As of 2024-06-29

Company Information

Elanco Animal Health Incorporated is an animal health company. The Company is focused in delivering products and services to prevent and treat disease in farm animals and pets. Its portfolio serves animals across its core species consisting of dogs, cats and cattle, poultry, swine, sheep and aqua. It offers products in two primary categories: Pet Health and Farm Animal. Its Pet Health portfolio is focused on parasiticides, vaccines and therapeutics. Its Pet Health portfolio products that protect pets from fleas, ticks and internal parasites. Its Farm Animal portfolio of products is primarily focused on cattle, swine, poultry, and aquaculture. Its Pet Health products include Advantage Family, Atopica, Claro/ Neptra, Credelio Family, Drontal Family, Galliprant, Interceptor Plus, Milbemax, Onsior, Seresto, Trifexis, and TruCan. Its Farm Animal products include AviPro, Baycox, Catosal, Comforta, Denagard, Experior, Hemicell, Maxiban, Monteban, Pulmotil, Rumensin, and others.

Contact Information

Headquarters
2500 Innovation Way NGREENFIELD, IN, United States 46140-9163
Phone
---
Fax
---

Executives

Independent Chairman of the Board
Lawrence Kurzius
President, Chief Executive Officer, Director
Jeffrey Simmons
Chief Financial Officer, Executive Vice President
Todd Young
Executive Vice President, General Counsel, Company Secretary
Shiv O'Neill
Executive Vice President, Human Resources, Corporate Communications and Administration
David Kinard

Ratings

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

Reports

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals

Market Cap
$7.1B
Revenue (TTM)
$4.4B
Shares Outstanding
494.2M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.42
EPS
$-2.64
Book Value
$12.63
P/E Ratio
-5.5x
Price/Sales (TTM)
1.6
Price/Cash Flow (TTM)
---
Operating Margin
-21.47%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Calendar

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.